169 related articles for article (PubMed ID: 30549085)
1. Reimbursement pricing for new medical devices in Japan: Is the evaluation of innovation appropriate?
Tamura M; Nakano S; Sugahara T
Int J Health Plann Manage; 2019 Apr; 34(2):583-593. PubMed ID: 30549085
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan.
Shiroiwa T
Int J Technol Assess Health Care; 2020 Jun; 36(3):270-276. PubMed ID: 32419677
[TBL] [Abstract][Full Text] [Related]
3. Current Medical Technology Reimbursement System in Japan.
Matsumoto T; Strachan L; Oyama S; Ishiguro Y; Lee SS
Value Health Reg Issues; 2023 Mar; 34():118-124. PubMed ID: 36696768
[TBL] [Abstract][Full Text] [Related]
4. How to value technological innovation: a proposal for determining relative clinical value.
Ladabaum U; Brill JV; Sonnenberg A; Shaheen NJ; Inadomi J; Wilcox CM; Park WG; Hur C; Pasricha PJ
Gastroenterology; 2013 Jan; 144(1):5-8. PubMed ID: 23153872
[No Abstract] [Full Text] [Related]
5. Medical device reimbursement coverage and pricing rules in Korea: current practice and issues with access to innovation.
Lee SS; Salole E
Value Health; 2014 Jun; 17(4):476-81. PubMed ID: 24969010
[TBL] [Abstract][Full Text] [Related]
6. Price disparity of percutaneous coronary intervention devices in Japan and the United States in 2006.
Yasunaga H; Ide H; Imamura T; Ohe K
Circ J; 2007 Jul; 71(7):1128-30. PubMed ID: 17587722
[TBL] [Abstract][Full Text] [Related]
7. Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years.
Kim S; Kim J; Cho H; Lee K; Ryu C; Lee JH
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):479-488. PubMed ID: 33275463
[No Abstract] [Full Text] [Related]
8. Pricing of medical devices under coverage uncertainty--a modelling approach.
Girling AJ; Lilford RJ; Young TP
Health Econ; 2012 Dec; 21(12):1502-7. PubMed ID: 22021085
[TBL] [Abstract][Full Text] [Related]
9. Diabetes device reimbursement in the EU-5.
Schäfer E; Schnell G; Bobáková T
J Diabetes Sci Technol; 2013 Jul; 7(4):1084-92. PubMed ID: 23911192
[TBL] [Abstract][Full Text] [Related]
10. Evolving reimbursement and pricing policies for devices in Europe and the United States should encourage greater value.
Sorenson C; Drummond M; Burns LR
Health Aff (Millwood); 2013 Apr; 32(4):788-96. PubMed ID: 23569060
[TBL] [Abstract][Full Text] [Related]
11. Price differences between Japan and the US for medical materials and how to reduce them.
Ide H; Yasunaga H; Imamura T; Ohe K
Health Policy; 2007 Jun; 82(1):71-7. PubMed ID: 17028042
[TBL] [Abstract][Full Text] [Related]
12. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T; Schreyögg J
Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
[TBL] [Abstract][Full Text] [Related]
13. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
Persson U; Norlin JM
Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
[TBL] [Abstract][Full Text] [Related]
14. Obtaining reimbursement in France and Italy for new diabetes products.
Schaefer E; Schnell G; Sonsalla J
J Diabetes Sci Technol; 2015 Jan; 9(1):156-61. PubMed ID: 25550411
[TBL] [Abstract][Full Text] [Related]
15. The need for greater price transparency in the medical device industry: an economic analysis.
Hahn RW; Klovers KB; Singer HJ
Health Aff (Millwood); 2008; 27(6):1554-9. PubMed ID: 18997211
[TBL] [Abstract][Full Text] [Related]
16. Current disparities in the prices of medical materials between Japan and the United States: further investigation of cardiovascular medical devices.
Yasunaga H; Ide H; Imamura T
J Cardiol; 2007 Feb; 49(2):77-81. PubMed ID: 17354581
[TBL] [Abstract][Full Text] [Related]
17. The reimbursement coverage decisions and pricing rules for medical devices in Taiwan.
Tsai HY; Huang YW; Chang SY; Huang LY; Lin CJ; Lee PC
GMS Health Innov Technol; 2022; 16():Doc02. PubMed ID: 35360087
[TBL] [Abstract][Full Text] [Related]
18. A comparative analysis of the impact of a positive list system on new chemical entity drugs and incrementally modified drugs in South Korea.
Ha D; Choi Y; Kim DU; Chung KH; Lee EK
Clin Ther; 2011 Jul; 33(7):926-32. PubMed ID: 21715008
[TBL] [Abstract][Full Text] [Related]
19. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
[TBL] [Abstract][Full Text] [Related]
20. Cross-national drug price comparisons with economic weights in external reference pricing in Germany.
Mahlich J; Sindern J; Suppliet M
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):37-43. PubMed ID: 30273062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
